Want to see XERS full AI Analyst Report?
XERS Stock Chart & Stats
$8.74
$0.03(0.36%)
At close: 4:00 PM EDT
$8.74
$0.03(0.36%)
Day’s Range― - ―
52-Week Range$5.25 - $10.08
Previous CloseN/A
Volume106.69K
Average Volume (3M)1.64M
Market Cap
$1.42B
Enterprise Value$1.54K
Total Cash (Recent Filing)$121.75M
Total Debt (Recent Filing)$289.44M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume1,569,573
30 Day Avg. Volume1,641,195
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.67Price Target Upside44.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$387.25M
Bulls Say, Bears Say
Bulls Say
Strong Revenue TrajectoryRapid revenue growth and tighter full-year guidance indicate broad commercial execution and improving demand across the portfolio. If sustained, this scale can strengthen operating leverage, support additional investment in the pipeline, and increase Xeris’s strategic relevance in specialty pharmaceutical markets.
High-margin Cash GenerationStrong gross profitability combined with positive and growing free cash flow provides an internal source of funding for commercialization and clinical development. This improves financial resilience and reduces reliance on external capital, although continued cash conversion remains important while net income is negative.
Commercial Momentum And Product ProtectionRecorlev’s exceptional growth demonstrates meaningful adoption in a specialty indication, while long-dated Keveyis intellectual-property protection supports durability in an ultra-rare market. Together, these products can reinforce recurring revenue and extend the value of Xeris’s commercial platform.
Bears Say
Fragile Capital StructureHigh debt alongside negative equity leaves a limited capital cushion and reduces flexibility during operating setbacks. Leverage can constrain future investment choices, increase dependence on sustained cash generation, and make refinancing or other financing decisions more consequential over the coming quarters.
Net Profitability Remains NegativeXeris has improved its operating trajectory, but continued net losses show that commercial progress has not yet translated into consistent bottom-line profitability. Persistent earnings volatility can limit internally funded growth and leaves the company more exposed to execution or spending pressures.
Rising Investment BurdenHigher commercial and research spending may enable Recorlev expansion and advance XP-8121, but it also raises the cost base before those investments generate returns. This can pressure near-term earnings and cash conversion, increasing execution requirements for the growth strategy.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $5.25 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.42B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 48 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.192.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -9.248%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (44.93% Upside)
$12.67 (44.93% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 78%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$12.67
▲(44.93% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
4.92% Insiders
10.49% Mutual Funds
10.46% Other Institutional Investors
60.13% Public Companies and
Individual Investors